دورية أكاديمية
أعرض في EDS

Formulation and Characterization of Doxycycline-Loaded Polymeric Nanoparticles for Testing Antitumor/Antiangiogenic Action in Experimental Colon Cancer in Mice.

التفاصيل البيبلوغرافية
العنوان: Formulation and Characterization of Doxycycline-Loaded Polymeric Nanoparticles for Testing Antitumor/Antiangiogenic Action in Experimental Colon Cancer in Mice.
المؤلفون: Alshaman R; Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia., Alattar A; Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia., El-Sayed RM; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, El-Arish 45511, Egypt., Gardouh AR; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.; Department of Pharmacy, Faculty of Pharmacy, Jadara University, Irbid 21110, Jordan., Elshaer RE; Department of Pathology, Faculty of Medicine, Al-Azhar University, Cairo 11651, Egypt., Elkazaz AY; Biochemistry and Molecular Biology Department, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt.; Biochemistry and Molecular Biology Department, Faculty of Medicine, Port Said University, Port Said 42526, Egypt., Eladl MA; Basic Medical Science Department, University of Sharjah, Sharjah 27272, United Arab Emirates., El-Sherbiny M; Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, Riyadh 71666, Saudi Arabia., Farag NE; Department of Physiology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt.; Department of Physiology, College of Medicine, Taif University, Taif 21974, Saudi Arabia., Hamdan AM; Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia., Zaitone SA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.
المصدر: Nanomaterials (Basel, Switzerland) [Nanomaterials (Basel)] 2022 Mar 03; Vol. 12 (5). Date of Electronic Publication: 2022 Mar 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101610216 Publication Model: Electronic Cited Medium: Print ISSN: 2079-4991 (Print) Linking ISSN: 20794991 NLM ISO Abbreviation: Nanomaterials (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2011]-
مستخلص: Nanotherapeutics can enhance the characteristics of drugs, such as rapid systemic clearance and systemic toxicities. Polymeric nanoparticles (PRNPs) depend on dispersion of a drug in an amorphous state in a polymer matrix. PRNPs are capable of delivering drugs and improving their safety. The primary goal of this study is to formulate doxycycline-loaded PRNPs by applying the nanoprecipitation method. Eudragit S100 (ES100) (for DOX-PRNP1) and hydroxypropyl methyl cellulose phthalate HP55 (for DOX-PRNP2) were tested as the drug carrying polymers and the DOX-PRNP2 showed better characteristics and drug release % and was hence selected to be tested in the biological study. Six different experimental groups were formed from sixty male albino mice. 1,2,-Dimethylhydrazine was used for 16 weeks to induce experimental colon cancer. We compared the oral administration of DOX-PRNP2 in doses of 5 and 10 mg/kg with the free drug. Results indicated that DOX-PRNP2 had greater antitumor activity, as evidenced by an improved histopathological picture for colon specimens as well as a decrease in the tumor scores. In addition, when compared to free DOX, the DOX-PRNP2 reduced the angiogenic indicators VEGD and CD31 to a greater extent. Collectively, the findings demonstrated that formulating DOX in PRNPs was useful in enhancing antitumor activity and can be used in other models of cancers to verify their efficacy and compatibility with our study.
References: Stem Cells Dev. 2006 Jun;15(3):305-13. (PMID: 16846369)
J Clin Oncol. 2005 Feb 10;23(5):1011-27. (PMID: 15585754)
J Ethnopharmacol. 2018 Jan 30;211:256-266. (PMID: 28807853)
J Natl Cancer Inst. 2015 Jun 24;107(9):. (PMID: 26109217)
J Control Release. 1998 Jan 2;50(1-3):31-40. (PMID: 9685870)
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. (PMID: 18287387)
Pharmacol Rev. 2004 Dec;56(4):549-80. (PMID: 15602010)
Pharmaceuticals (Basel). 2020 Jan 08;13(1):. (PMID: 31936208)
Mater Sci Eng C Mater Biol Appl. 2016 Mar;60:569-578. (PMID: 26706565)
Pharmacol Rep. 2008 Sep-Oct;60(5):742-9. (PMID: 19066422)
Drug Des Devel Ther. 2013 Jul 17;7:585-99. (PMID: 23898223)
J Vis Exp. 2019 Jan 7;(143):. (PMID: 30663705)
Open Access Maced J Med Sci. 2019 Jul 20;7(14):2391-2398. (PMID: 31592285)
J Natl Cancer Inst. 2017 Aug 1;109(8):. (PMID: 28376186)
J Clin Oncol. 2000 Aug;18(16):2938-47. (PMID: 10944126)
Ultrastruct Pathol. 2012 Oct;36(5):336-42. (PMID: 22574784)
J Control Release. 2019 May 10;301:62-75. (PMID: 30876953)
Int J Mol Med. 2015 Apr;35(4):995-1002. (PMID: 25672594)
J Exp Clin Cancer Res. 2010 Jun 16;29:71. (PMID: 20565704)
Pharmacol Res. 2011 Dec;64(6):614-23. (PMID: 21843641)
Int Immunopharmacol. 2017 Mar;44:72-86. (PMID: 28088698)
Biol Trace Elem Res. 2009 Dec;132(1-3):184-96. (PMID: 19396405)
Cancer Res. 1995 Sep 15;55(18):3964-8. (PMID: 7664263)
Biomed Pharmacother. 2018 Dec;108:1415-1424. (PMID: 30372844)
BMC Cancer. 2015 Oct 21;15:752. (PMID: 26486165)
Int J Pharm. 2016 Nov 30;514(1):24-40. (PMID: 27863668)
Chem Biol Interact. 2018 Nov 1;295:52-63. (PMID: 29678497)
Curr Drug Targets. 2018 Feb 19;19(4):300-317. (PMID: 27262486)
Oncogene. 2015 Jun 11;34(24):3107-19. (PMID: 25151964)
Front Oncol. 2018 Oct 12;8:452. (PMID: 30364293)
Lancet. 2013 Jan 26;381(9863):303-12. (PMID: 23177514)
Nat Med. 2012 Nov;18(11):1639-42. (PMID: 23104132)
Chem Rev. 2016 Feb 24;116(4):2602-63. (PMID: 26854975)
Chem Rev. 2016 May 11;116(9):5338-431. (PMID: 27109701)
Nat Rev Cancer. 2010 Jul;10(7):505-14. (PMID: 20574450)
J Pineal Res. 2019 Sep;67(2):e12585. (PMID: 31066091)
Nat Rev Cancer. 2017 Jan;17(1):20-37. (PMID: 27834398)
Molecules. 2020 Jul 15;25(14):. (PMID: 32679837)
Methods Enzymol. 2012;509:61-85. (PMID: 22568901)
Molecules. 2021 May 19;26(10):. (PMID: 34069585)
Pharmacol Res. 2011 Feb;63(2):102-7. (PMID: 20951211)
Tumour Biol. 2017 Jun;39(6):1010428317712445. (PMID: 28639898)
J Clin Oncol. 1999 Nov;17(11):3560-8. (PMID: 10550155)
Oncotarget. 2015 Mar 10;6(7):4569-84. (PMID: 25625193)
Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44. (PMID: 17601629)
Clin Cancer Res. 2005 Oct 15;11(20):7480-9. (PMID: 16243822)
Tumour Biol. 2015 Dec;36(12):9267-75. (PMID: 26099723)
AAPS PharmSciTech. 2021 Oct 19;22(8):252. (PMID: 34668089)
Pharmaceutics. 2020 Mar 26;12(4):. (PMID: 32224875)
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732. (PMID: 31455888)
Int J Pharm. 2017 Oct 30;532(1):66-81. (PMID: 28801107)
Mol Cancer. 2019 Mar 30;18(1):68. (PMID: 30927911)
Int J Mol Sci. 2021 May 14;22(10):. (PMID: 34069111)
Nat Med. 1995 Jan;1(1):27-31. (PMID: 7584949)
Pharmaceutics. 2020 Jul 15;12(7):. (PMID: 32679809)
J Pharm Pharm Sci. 2011;14(1):67-77. (PMID: 21501554)
J Control Release. 2001 Jan 29;70(1-2):1-20. (PMID: 11166403)
Br J Pharmacol. 2013 May;169(2):337-52. (PMID: 23441623)
PLoS One. 2014 Jun 27;9(6):e100562. (PMID: 24971882)
Nat Med. 1998 Jan;4(1):13-4. (PMID: 9427594)
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):524-539. (PMID: 30784319)
Biomolecules. 2021 Jan 15;11(1):. (PMID: 33467560)
Oncol Lett. 2012 Oct;4(4):763-766. (PMID: 23205098)
Curr Pharm Des. 2014;20(7):1041-4. (PMID: 23755727)
Nat Med. 2003 Jun;9(6):669-76. (PMID: 12778165)
Oncotarget. 2015 Jun 10;6(16):14005-25. (PMID: 26087309)
Mol Pharm. 2019 Oct 7;16(10):4104-4120. (PMID: 31517495)
Sci Rep. 2020 Mar 9;10(1):4363. (PMID: 32152409)
ACS Nano. 2013 Mar 26;7(3):2056-67. (PMID: 23413798)
Front Pharmacol. 2021 Jun 28;12:708785. (PMID: 34262464)
Tumour Biol. 2016 Sep;37(9):11553-11572. (PMID: 27260630)
Gels. 2020 Feb 04;6(1):. (PMID: 32033057)
Toxicol Mech Methods. 2021 Feb;31(2):138-149. (PMID: 33190582)
J Toxicol Pathol. 2013 Dec;26(4):335-41. (PMID: 24526805)
Sci Rep. 2018 Apr 4;8(1):5599. (PMID: 29618792)
Res Pharm Sci. 2017 Feb;12(1):1-14. (PMID: 28255308)
Mol Pharm. 2016 Jun 6;13(6):2084-94. (PMID: 27144397)
ACS Omega. 2018 Jan 31;3(1):1220-1230. (PMID: 30023798)
Med Oncol. 2010 Jun;27(2):304-9. (PMID: 19340613)
Sci Rep. 2020 Jan 24;10(1):1129. (PMID: 31980686)
Annu Rev Med. 2010;61:359-73. (PMID: 20059343)
معلومات مُعتمدة: S-1441-0164 Deanship of scientific research at the University of Tabuk
فهرسة مساهمة: Keywords: angiogenesis; doxycycline polymeric nanoparticles; eudragit S100; hydroxypropyl methylcellulose phthalate; mouse colon cancer; nanoprecipitation method
تواريخ الأحداث: Date Created: 20220310 Latest Revision: 20220316
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8912660
DOI: 10.3390/nano12050857
PMID: 35269343
قاعدة البيانات: MEDLINE
الوصف
تدمد:2079-4991
DOI:10.3390/nano12050857